Mesoblast

MESONasdaq Australia Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.058 B

$15.94 +2.05%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

—

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#33VericelVCEL$2.31B
#34Adma BiologicsADMA$2.22B
#35MesoblastMESO$2.06B
#36Taysha Gene TherapiesTSHA$1.89B
#37Recursion PharmaceuticalsRXRX$1.72B

Where these numbers come from

Share counts and financials for Mesoblast are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.